Definitive CPACS evidence wouldn't arrive for ~12 months thanks to the ~6 month delay in trial commencement.
We're at risk of torching the next two lots of options.
That's why I think they sign a licensing deal near term (next ~3 months). There's no strategic benefit in waiting as we're at risk of greater dilution at a lower cost price if these options are torched and we dwindle down on funds (read: IMU/CHM etc.). Settle with licensing a smaller geographic region/s near term and sit on the larger markets for licensing post validation.
RAC Price at posting:
$1.34 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)